Review





Similar Products

99
Roche kapa stranded mrna seq kit with poly a selection
Kapa Stranded Mrna Seq Kit With Poly A Selection, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kapa stranded mrna seq kit with poly a selection/product/Roche
Average 99 stars, based on 1 article reviews
kapa stranded mrna seq kit with poly a selection - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Roche kapa stranded mrna seq kit
Kapa Stranded Mrna Seq Kit, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kapa stranded mrna seq kit/product/Roche
Average 99 stars, based on 1 article reviews
kapa stranded mrna seq kit - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Roche kapa rna hyperprep kit with riboerase hmr
Kapa Rna Hyperprep Kit With Riboerase Hmr, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kapa rna hyperprep kit with riboerase hmr/product/Roche
Average 99 stars, based on 1 article reviews
kapa rna hyperprep kit with riboerase hmr - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Roche rna seq libraries
A. Volcano map showing the DARs (Differentially Accessible Regions) in LHCN-M2 cells after SMCHD1 knockout. DARs detected by ATAC-seq with FDR <= 0.05 and log2 fold change >2 were labeled in light blue and red, respectively. B. Gene functional analysis of increased DARs upon SMCHD1 knockout. C. Gene functional analysis of decreased DARs upon SMCHD1 knockout. D. Profile plots of ATAC-seq showing increased chromatin accessibility at the promoters of upregulated genes, and reduced chromatin accessibility at the promoters of down-regulated genes caused by SMCHD1 depletion. A paired t-test was used for statistical analysis for calculating chromatin accessibility differences. E. IGV browser views of ATAC-seq peaks <t>and</t> <t>RNA-seq</t> peaks at the promoter regions of genes showing down-regulation ( H2AFJ and SELENBP1 ) and up-regulation ( CCL2 and NAP1L3 ). F. Motif analysis of increased and reduced DARs.
Rna Seq Libraries, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rna seq libraries/product/Roche
Average 99 stars, based on 1 article reviews
rna seq libraries - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Roche ribosome rnas by riboerase
RNA editing and protein level changes caused by the G1007R mutation (A) RNA editing levels in well-defined RNA editing sites. Data were assessed by RT-PCR Sanger sequencing on brain <t>RNAs</t> from WT and Adar WT/G1007R mice. Editing levels at the A site in Htr2c mRNA and editing in mRNAs of Blcap and Ube2o are modestly decreased, while editing at other sites are not different from the WT controls, and the D site in the Htr2c mRNA, known to be the ADAR2 editing site, is increased. Data are presented as mean ± SD, n = 4 for both WT and Adar WT/G1007R mice. The Prism t test was used to test the differences between the two groups. ∗ p < 0.05, ∗∗∗ p < 0.001. (B) RNA editing site numbers in WT and Adar WT/G1007R mice. Data were assessed through deep RNA-seq data analysis. The total numbers of RNA editing sites in each brain samples were averaged in the WT and Adar WT/G1007R groups. The numbers of editing sites are not significantly different between the two groups. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. The average editing levels are not different. (C) Overall averaged RNA editing levels are shown. Three mice in each group were assessed from the RNA-seq data. A value of 1.0 indicates 100% editing. (D) RNA editing levels at editing sites in repetitive sequences. The averaged value of the editing sites in the WT and the Adar WT/G1007R mice are shown. There is no significant difference between the WT and Adar WT/G1007R mice. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between the two groups. (E) RNA editing efficiency at individual editing sites. Sites include the well-defined editing sites in Gria2 , Gria3 , Griak , and Htrc2 mRNAs, and data were calculated from the RNA-seq data. Editing at the known editing sites for ADAR1, including the A and B sites in Htrc2 mRNA, in the Blcap , Neil1 , Ube2o mRNAs was significantly decreased. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗ p < 0.05, ∗∗ p < 0.01. (F) ADAR1 protein levels in the brain from individual mice. Data were assessed by western blot with a specific antibody recognizing both the p150 and p110 isoforms of ADAR1. The p110 isoform is predominantly expressed in the brain. The ADAR1 protein level is dramatically decreased in the Adar WT/G1007R mice. (G) Averaged ADAR1 protein levels for WT and Adar WT/G1007R mice. Protein level of p110 isoform was quantified by the density of the protein signals on western blots from independent experiments. The ADAR1 protein level in the Adar WT/G1007R mice is significantly lower than the WT controls. Data are presented as mean ± SD, n = 6 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗∗∗ p < 0.001.
Ribosome Rnas By Riboerase, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ribosome rnas by riboerase/product/Roche
Average 99 stars, based on 1 article reviews
ribosome rnas by riboerase - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Roche kapa stranded mrna seq library prep kit
RNA editing and protein level changes caused by the G1007R mutation (A) RNA editing levels in well-defined RNA editing sites. Data were assessed by RT-PCR Sanger sequencing on brain <t>RNAs</t> from WT and Adar WT/G1007R mice. Editing levels at the A site in Htr2c mRNA and editing in mRNAs of Blcap and Ube2o are modestly decreased, while editing at other sites are not different from the WT controls, and the D site in the Htr2c mRNA, known to be the ADAR2 editing site, is increased. Data are presented as mean ± SD, n = 4 for both WT and Adar WT/G1007R mice. The Prism t test was used to test the differences between the two groups. ∗ p < 0.05, ∗∗∗ p < 0.001. (B) RNA editing site numbers in WT and Adar WT/G1007R mice. Data were assessed through deep RNA-seq data analysis. The total numbers of RNA editing sites in each brain samples were averaged in the WT and Adar WT/G1007R groups. The numbers of editing sites are not significantly different between the two groups. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. The average editing levels are not different. (C) Overall averaged RNA editing levels are shown. Three mice in each group were assessed from the RNA-seq data. A value of 1.0 indicates 100% editing. (D) RNA editing levels at editing sites in repetitive sequences. The averaged value of the editing sites in the WT and the Adar WT/G1007R mice are shown. There is no significant difference between the WT and Adar WT/G1007R mice. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between the two groups. (E) RNA editing efficiency at individual editing sites. Sites include the well-defined editing sites in Gria2 , Gria3 , Griak , and Htrc2 mRNAs, and data were calculated from the RNA-seq data. Editing at the known editing sites for ADAR1, including the A and B sites in Htrc2 mRNA, in the Blcap , Neil1 , Ube2o mRNAs was significantly decreased. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗ p < 0.05, ∗∗ p < 0.01. (F) ADAR1 protein levels in the brain from individual mice. Data were assessed by western blot with a specific antibody recognizing both the p150 and p110 isoforms of ADAR1. The p110 isoform is predominantly expressed in the brain. The ADAR1 protein level is dramatically decreased in the Adar WT/G1007R mice. (G) Averaged ADAR1 protein levels for WT and Adar WT/G1007R mice. Protein level of p110 isoform was quantified by the density of the protein signals on western blots from independent experiments. The ADAR1 protein level in the Adar WT/G1007R mice is significantly lower than the WT controls. Data are presented as mean ± SD, n = 6 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗∗∗ p < 0.001.
Kapa Stranded Mrna Seq Library Prep Kit, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kapa stranded mrna seq library prep kit/product/Roche
Average 99 stars, based on 1 article reviews
kapa stranded mrna seq library prep kit - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Roche ribo erase roche cat
RNA editing and protein level changes caused by the G1007R mutation (A) RNA editing levels in well-defined RNA editing sites. Data were assessed by RT-PCR Sanger sequencing on brain <t>RNAs</t> from WT and Adar WT/G1007R mice. Editing levels at the A site in Htr2c mRNA and editing in mRNAs of Blcap and Ube2o are modestly decreased, while editing at other sites are not different from the WT controls, and the D site in the Htr2c mRNA, known to be the ADAR2 editing site, is increased. Data are presented as mean ± SD, n = 4 for both WT and Adar WT/G1007R mice. The Prism t test was used to test the differences between the two groups. ∗ p < 0.05, ∗∗∗ p < 0.001. (B) RNA editing site numbers in WT and Adar WT/G1007R mice. Data were assessed through deep RNA-seq data analysis. The total numbers of RNA editing sites in each brain samples were averaged in the WT and Adar WT/G1007R groups. The numbers of editing sites are not significantly different between the two groups. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. The average editing levels are not different. (C) Overall averaged RNA editing levels are shown. Three mice in each group were assessed from the RNA-seq data. A value of 1.0 indicates 100% editing. (D) RNA editing levels at editing sites in repetitive sequences. The averaged value of the editing sites in the WT and the Adar WT/G1007R mice are shown. There is no significant difference between the WT and Adar WT/G1007R mice. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between the two groups. (E) RNA editing efficiency at individual editing sites. Sites include the well-defined editing sites in Gria2 , Gria3 , Griak , and Htrc2 mRNAs, and data were calculated from the RNA-seq data. Editing at the known editing sites for ADAR1, including the A and B sites in Htrc2 mRNA, in the Blcap , Neil1 , Ube2o mRNAs was significantly decreased. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗ p < 0.05, ∗∗ p < 0.01. (F) ADAR1 protein levels in the brain from individual mice. Data were assessed by western blot with a specific antibody recognizing both the p150 and p110 isoforms of ADAR1. The p110 isoform is predominantly expressed in the brain. The ADAR1 protein level is dramatically decreased in the Adar WT/G1007R mice. (G) Averaged ADAR1 protein levels for WT and Adar WT/G1007R mice. Protein level of p110 isoform was quantified by the density of the protein signals on western blots from independent experiments. The ADAR1 protein level in the Adar WT/G1007R mice is significantly lower than the WT controls. Data are presented as mean ± SD, n = 6 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗∗∗ p < 0.001.
Ribo Erase Roche Cat, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ribo erase roche cat/product/Roche
Average 99 stars, based on 1 article reviews
ribo erase roche cat - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Roche ribo erase kit
RNA editing and protein level changes caused by the G1007R mutation (A) RNA editing levels in well-defined RNA editing sites. Data were assessed by RT-PCR Sanger sequencing on brain <t>RNAs</t> from WT and Adar WT/G1007R mice. Editing levels at the A site in Htr2c mRNA and editing in mRNAs of Blcap and Ube2o are modestly decreased, while editing at other sites are not different from the WT controls, and the D site in the Htr2c mRNA, known to be the ADAR2 editing site, is increased. Data are presented as mean ± SD, n = 4 for both WT and Adar WT/G1007R mice. The Prism t test was used to test the differences between the two groups. ∗ p < 0.05, ∗∗∗ p < 0.001. (B) RNA editing site numbers in WT and Adar WT/G1007R mice. Data were assessed through deep RNA-seq data analysis. The total numbers of RNA editing sites in each brain samples were averaged in the WT and Adar WT/G1007R groups. The numbers of editing sites are not significantly different between the two groups. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. The average editing levels are not different. (C) Overall averaged RNA editing levels are shown. Three mice in each group were assessed from the RNA-seq data. A value of 1.0 indicates 100% editing. (D) RNA editing levels at editing sites in repetitive sequences. The averaged value of the editing sites in the WT and the Adar WT/G1007R mice are shown. There is no significant difference between the WT and Adar WT/G1007R mice. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between the two groups. (E) RNA editing efficiency at individual editing sites. Sites include the well-defined editing sites in Gria2 , Gria3 , Griak , and Htrc2 mRNAs, and data were calculated from the RNA-seq data. Editing at the known editing sites for ADAR1, including the A and B sites in Htrc2 mRNA, in the Blcap , Neil1 , Ube2o mRNAs was significantly decreased. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗ p < 0.05, ∗∗ p < 0.01. (F) ADAR1 protein levels in the brain from individual mice. Data were assessed by western blot with a specific antibody recognizing both the p150 and p110 isoforms of ADAR1. The p110 isoform is predominantly expressed in the brain. The ADAR1 protein level is dramatically decreased in the Adar WT/G1007R mice. (G) Averaged ADAR1 protein levels for WT and Adar WT/G1007R mice. Protein level of p110 isoform was quantified by the density of the protein signals on western blots from independent experiments. The ADAR1 protein level in the Adar WT/G1007R mice is significantly lower than the WT controls. Data are presented as mean ± SD, n = 6 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗∗∗ p < 0.001.
Ribo Erase Kit, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ribo erase kit/product/Roche
Average 99 stars, based on 1 article reviews
ribo erase kit - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


A. Volcano map showing the DARs (Differentially Accessible Regions) in LHCN-M2 cells after SMCHD1 knockout. DARs detected by ATAC-seq with FDR <= 0.05 and log2 fold change >2 were labeled in light blue and red, respectively. B. Gene functional analysis of increased DARs upon SMCHD1 knockout. C. Gene functional analysis of decreased DARs upon SMCHD1 knockout. D. Profile plots of ATAC-seq showing increased chromatin accessibility at the promoters of upregulated genes, and reduced chromatin accessibility at the promoters of down-regulated genes caused by SMCHD1 depletion. A paired t-test was used for statistical analysis for calculating chromatin accessibility differences. E. IGV browser views of ATAC-seq peaks and RNA-seq peaks at the promoter regions of genes showing down-regulation ( H2AFJ and SELENBP1 ) and up-regulation ( CCL2 and NAP1L3 ). F. Motif analysis of increased and reduced DARs.

Journal: bioRxiv

Article Title: SMCHD1 loss re-wires MYOD1 enhancer nexuses and chromatin accessibility landscapes in muscle cells

doi: 10.64898/2026.02.21.707202

Figure Lengend Snippet: A. Volcano map showing the DARs (Differentially Accessible Regions) in LHCN-M2 cells after SMCHD1 knockout. DARs detected by ATAC-seq with FDR <= 0.05 and log2 fold change >2 were labeled in light blue and red, respectively. B. Gene functional analysis of increased DARs upon SMCHD1 knockout. C. Gene functional analysis of decreased DARs upon SMCHD1 knockout. D. Profile plots of ATAC-seq showing increased chromatin accessibility at the promoters of upregulated genes, and reduced chromatin accessibility at the promoters of down-regulated genes caused by SMCHD1 depletion. A paired t-test was used for statistical analysis for calculating chromatin accessibility differences. E. IGV browser views of ATAC-seq peaks and RNA-seq peaks at the promoter regions of genes showing down-regulation ( H2AFJ and SELENBP1 ) and up-regulation ( CCL2 and NAP1L3 ). F. Motif analysis of increased and reduced DARs.

Article Snippet: RNA-seq libraries were prepared from total RNA with the KAPA RNA HyperPrep Kit (KAPA Biosystems, KR1351) according to the manufacturer’s protocols.

Techniques: Knock-Out, Labeling, Functional Assay, RNA Sequencing

A. Illustration of RNA-seq peaks at MYOD1 gene locus. B. Illustration of RNA-seq peaks at MYF5 gene locus. C. Illustration of RNA-seq peaks at JUN family genes loci. D. Illustration of RNA-seq peaks at FOS family genes loci.

Journal: bioRxiv

Article Title: SMCHD1 loss re-wires MYOD1 enhancer nexuses and chromatin accessibility landscapes in muscle cells

doi: 10.64898/2026.02.21.707202

Figure Lengend Snippet: A. Illustration of RNA-seq peaks at MYOD1 gene locus. B. Illustration of RNA-seq peaks at MYF5 gene locus. C. Illustration of RNA-seq peaks at JUN family genes loci. D. Illustration of RNA-seq peaks at FOS family genes loci.

Article Snippet: RNA-seq libraries were prepared from total RNA with the KAPA RNA HyperPrep Kit (KAPA Biosystems, KR1351) according to the manufacturer’s protocols.

Techniques: RNA Sequencing

A. The donut pie chart shows the fraction of MYOD1 binding sites in genome compartments of wildtype myoblasts. B. Motif analysis of MYOD1 binding sites. C. Profile plot of MYOD1 ChIP-seq showing increased MYOD1 enrichment at increased chromatin accessibility regions detected by ATAC-seq (upper panel). Significance of the differences (paired t-test), the line above the dash line ( q -value < 0.05) indicates a statistically significant difference of KO versus WT cells (lower panel). D. Profile plot of MYOD1 ChIP-seq showing decreased MYOD1 enrichment at reduced chromatin accessibility regions detected by ATAC-seq (upper panel). Significance of the differences (paired t-test), the line above the dash line ( q -value < 0.05) indicates a statistically significant difference of KO versus WT cells (lower panel). E. Volcano plot showing the differential binding sites of MYOD1 after SMCHD1 knockout. All differential binding sites with FDR <= 0.05 and log2 fold change >2 were labeled in light blue and red. F. Volcano plot showing the expression of differential MYOD1 binding genes. Differentially expressed genes with FDR <= 0.05 and log2 fold change >2 were labeled in light blue and red. G. Illustration of ATAC-seq peaks, RNA-seq peaks and MYOD1 binding sites at the CCL2 gene locus. H. Bar chart showing the fraction of differential MYOD1 binding sites in different chromatin states.

Journal: bioRxiv

Article Title: SMCHD1 loss re-wires MYOD1 enhancer nexuses and chromatin accessibility landscapes in muscle cells

doi: 10.64898/2026.02.21.707202

Figure Lengend Snippet: A. The donut pie chart shows the fraction of MYOD1 binding sites in genome compartments of wildtype myoblasts. B. Motif analysis of MYOD1 binding sites. C. Profile plot of MYOD1 ChIP-seq showing increased MYOD1 enrichment at increased chromatin accessibility regions detected by ATAC-seq (upper panel). Significance of the differences (paired t-test), the line above the dash line ( q -value < 0.05) indicates a statistically significant difference of KO versus WT cells (lower panel). D. Profile plot of MYOD1 ChIP-seq showing decreased MYOD1 enrichment at reduced chromatin accessibility regions detected by ATAC-seq (upper panel). Significance of the differences (paired t-test), the line above the dash line ( q -value < 0.05) indicates a statistically significant difference of KO versus WT cells (lower panel). E. Volcano plot showing the differential binding sites of MYOD1 after SMCHD1 knockout. All differential binding sites with FDR <= 0.05 and log2 fold change >2 were labeled in light blue and red. F. Volcano plot showing the expression of differential MYOD1 binding genes. Differentially expressed genes with FDR <= 0.05 and log2 fold change >2 were labeled in light blue and red. G. Illustration of ATAC-seq peaks, RNA-seq peaks and MYOD1 binding sites at the CCL2 gene locus. H. Bar chart showing the fraction of differential MYOD1 binding sites in different chromatin states.

Article Snippet: RNA-seq libraries were prepared from total RNA with the KAPA RNA HyperPrep Kit (KAPA Biosystems, KR1351) according to the manufacturer’s protocols.

Techniques: Binding Assay, ChIP-sequencing, Knock-Out, Labeling, Expressing, RNA Sequencing

A. Correlation between MYOD1 binding and altered gene expression. Pearson’s correlation coefficient was calculated with R to determine the strength and direction of the relationship between altered MYOD1 binding and altered gene expression. B-D. Illustration of RNA-seq peaks, ATAC-seq, H3K4me1, H3K27Ac, and MYOD1 ChIP seq at representative upregulated gene loci. E-F. Illustration of RNA-seq peaks, ATAC-seq, H3K4me1, H3K27Ac, and MYOD1 ChIP seq at representative downregulated gene loci.

Journal: bioRxiv

Article Title: SMCHD1 loss re-wires MYOD1 enhancer nexuses and chromatin accessibility landscapes in muscle cells

doi: 10.64898/2026.02.21.707202

Figure Lengend Snippet: A. Correlation between MYOD1 binding and altered gene expression. Pearson’s correlation coefficient was calculated with R to determine the strength and direction of the relationship between altered MYOD1 binding and altered gene expression. B-D. Illustration of RNA-seq peaks, ATAC-seq, H3K4me1, H3K27Ac, and MYOD1 ChIP seq at representative upregulated gene loci. E-F. Illustration of RNA-seq peaks, ATAC-seq, H3K4me1, H3K27Ac, and MYOD1 ChIP seq at representative downregulated gene loci.

Article Snippet: RNA-seq libraries were prepared from total RNA with the KAPA RNA HyperPrep Kit (KAPA Biosystems, KR1351) according to the manufacturer’s protocols.

Techniques: Binding Assay, Gene Expression, RNA Sequencing, ChIP-sequencing

RNA editing and protein level changes caused by the G1007R mutation (A) RNA editing levels in well-defined RNA editing sites. Data were assessed by RT-PCR Sanger sequencing on brain RNAs from WT and Adar WT/G1007R mice. Editing levels at the A site in Htr2c mRNA and editing in mRNAs of Blcap and Ube2o are modestly decreased, while editing at other sites are not different from the WT controls, and the D site in the Htr2c mRNA, known to be the ADAR2 editing site, is increased. Data are presented as mean ± SD, n = 4 for both WT and Adar WT/G1007R mice. The Prism t test was used to test the differences between the two groups. ∗ p < 0.05, ∗∗∗ p < 0.001. (B) RNA editing site numbers in WT and Adar WT/G1007R mice. Data were assessed through deep RNA-seq data analysis. The total numbers of RNA editing sites in each brain samples were averaged in the WT and Adar WT/G1007R groups. The numbers of editing sites are not significantly different between the two groups. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. The average editing levels are not different. (C) Overall averaged RNA editing levels are shown. Three mice in each group were assessed from the RNA-seq data. A value of 1.0 indicates 100% editing. (D) RNA editing levels at editing sites in repetitive sequences. The averaged value of the editing sites in the WT and the Adar WT/G1007R mice are shown. There is no significant difference between the WT and Adar WT/G1007R mice. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between the two groups. (E) RNA editing efficiency at individual editing sites. Sites include the well-defined editing sites in Gria2 , Gria3 , Griak , and Htrc2 mRNAs, and data were calculated from the RNA-seq data. Editing at the known editing sites for ADAR1, including the A and B sites in Htrc2 mRNA, in the Blcap , Neil1 , Ube2o mRNAs was significantly decreased. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗ p < 0.05, ∗∗ p < 0.01. (F) ADAR1 protein levels in the brain from individual mice. Data were assessed by western blot with a specific antibody recognizing both the p150 and p110 isoforms of ADAR1. The p110 isoform is predominantly expressed in the brain. The ADAR1 protein level is dramatically decreased in the Adar WT/G1007R mice. (G) Averaged ADAR1 protein levels for WT and Adar WT/G1007R mice. Protein level of p110 isoform was quantified by the density of the protein signals on western blots from independent experiments. The ADAR1 protein level in the Adar WT/G1007R mice is significantly lower than the WT controls. Data are presented as mean ± SD, n = 6 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗∗∗ p < 0.001.

Journal: iScience

Article Title: Heterozygous ADAR mutant mice exhibit RNA sensing-dependent neuroinflammation and phenotypes associated with Aicardi-Goutières syndrome

doi: 10.1016/j.isci.2026.114758

Figure Lengend Snippet: RNA editing and protein level changes caused by the G1007R mutation (A) RNA editing levels in well-defined RNA editing sites. Data were assessed by RT-PCR Sanger sequencing on brain RNAs from WT and Adar WT/G1007R mice. Editing levels at the A site in Htr2c mRNA and editing in mRNAs of Blcap and Ube2o are modestly decreased, while editing at other sites are not different from the WT controls, and the D site in the Htr2c mRNA, known to be the ADAR2 editing site, is increased. Data are presented as mean ± SD, n = 4 for both WT and Adar WT/G1007R mice. The Prism t test was used to test the differences between the two groups. ∗ p < 0.05, ∗∗∗ p < 0.001. (B) RNA editing site numbers in WT and Adar WT/G1007R mice. Data were assessed through deep RNA-seq data analysis. The total numbers of RNA editing sites in each brain samples were averaged in the WT and Adar WT/G1007R groups. The numbers of editing sites are not significantly different between the two groups. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. The average editing levels are not different. (C) Overall averaged RNA editing levels are shown. Three mice in each group were assessed from the RNA-seq data. A value of 1.0 indicates 100% editing. (D) RNA editing levels at editing sites in repetitive sequences. The averaged value of the editing sites in the WT and the Adar WT/G1007R mice are shown. There is no significant difference between the WT and Adar WT/G1007R mice. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between the two groups. (E) RNA editing efficiency at individual editing sites. Sites include the well-defined editing sites in Gria2 , Gria3 , Griak , and Htrc2 mRNAs, and data were calculated from the RNA-seq data. Editing at the known editing sites for ADAR1, including the A and B sites in Htrc2 mRNA, in the Blcap , Neil1 , Ube2o mRNAs was significantly decreased. n = 3 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗ p < 0.05, ∗∗ p < 0.01. (F) ADAR1 protein levels in the brain from individual mice. Data were assessed by western blot with a specific antibody recognizing both the p150 and p110 isoforms of ADAR1. The p110 isoform is predominantly expressed in the brain. The ADAR1 protein level is dramatically decreased in the Adar WT/G1007R mice. (G) Averaged ADAR1 protein levels for WT and Adar WT/G1007R mice. Protein level of p110 isoform was quantified by the density of the protein signals on western blots from independent experiments. The ADAR1 protein level in the Adar WT/G1007R mice is significantly lower than the WT controls. Data are presented as mean ± SD, n = 6 for both WT and Adar WT/G1007R groups. The Prism t test was used to test the differences between groups. ∗∗∗ p < 0.001.

Article Snippet: Nine independent RNA libraries were generated using the KAPA RNA HyperPrep Kit with the removal of ribosome RNAs by RiboErase (Kapa Biosystems) according to the manufacturer’s protocol, and the libraries were sequenced using the NovaSeq6000 platform (Illumina) to an average of 80M 10o bp paired end reads.

Techniques: Mutagenesis, Reverse Transcription Polymerase Chain Reaction, Sequencing, RNA Sequencing, Western Blot

The G1007R mutation causes alternative splicing in Adar G1007R/G1007R mice (A) ADAR1 protein levels in embryos. Total protein from E11.5-day embryos of Adar WT/G1007R mating was analyzed by western blot with anti-ADAR1 antibody. The p110 isoform of ADAR1 is expressed in the WT embryos, and the p150 isoform is undetected. The p110 isoform in Adar G1007R/G1007R embryos is dramatically reduced compared to WT, while the p150 isoform is detectable. Quantification of p150 and p110 isoforms is shown on the right, showing dramatically reduced p110 in Adar G1007R/G1007R embryos. Data are presented as mean ± SD, n = 3. The Prism t test was used to test the differences between the two groups. ∗∗∗ p < 0.001. (B) ADAR1 protein levels in brain. Total protein from brains was isolated from two-week-old mice. The p110 isoform of ADAR1 is detected in both the mutant and WT mice, but the quantity in the mutant mice is much less, while the p150 isoform was not detected. Quantification of p110 isoform is shown on the right, showing dramatically reduced p110 in Adar G1007R/G1007R ; Ifih1 −/− brains. Data are presented as mean ± SD, n = 3. The Prism t test was used to test the differences between the two groups. ∗∗∗ p < 0.001. (C) cDNA alignment shows altered sequences. The cDNA clones of the E11.5-day Adar G1007R/G1007R embryonic total RNAs were subjected to Sanger sequencing. The cDNA sequences covering the region of exon 10 to exon 13 are compared between the Adar G1007R/G1007R and WT embryos . The sequences of the corresponding exons are indicated by alternative colors. The G>A mutation site is highlighted in red and boxed. The dashes indicate the missing sequences, including the missing exon 11, exon 12, or the 27 nucleotides in 3′end of exon 11. The seven extra nucleotides highlighted in blue are from intron 11. Five different mRNA sequences containing different exons or intron are shown here. (D) The genetic G>A mutation (G1007R) at 3′ end of exon 11 in the Adar gene alters the TG splice donor site sequence to TA. A chromatogram from Sanger sequencing of a heterozygous genome flanking the mutation site is shown. The donor site is boxed, and the mutation is indicated by an arrow.

Journal: iScience

Article Title: Heterozygous ADAR mutant mice exhibit RNA sensing-dependent neuroinflammation and phenotypes associated with Aicardi-Goutières syndrome

doi: 10.1016/j.isci.2026.114758

Figure Lengend Snippet: The G1007R mutation causes alternative splicing in Adar G1007R/G1007R mice (A) ADAR1 protein levels in embryos. Total protein from E11.5-day embryos of Adar WT/G1007R mating was analyzed by western blot with anti-ADAR1 antibody. The p110 isoform of ADAR1 is expressed in the WT embryos, and the p150 isoform is undetected. The p110 isoform in Adar G1007R/G1007R embryos is dramatically reduced compared to WT, while the p150 isoform is detectable. Quantification of p150 and p110 isoforms is shown on the right, showing dramatically reduced p110 in Adar G1007R/G1007R embryos. Data are presented as mean ± SD, n = 3. The Prism t test was used to test the differences between the two groups. ∗∗∗ p < 0.001. (B) ADAR1 protein levels in brain. Total protein from brains was isolated from two-week-old mice. The p110 isoform of ADAR1 is detected in both the mutant and WT mice, but the quantity in the mutant mice is much less, while the p150 isoform was not detected. Quantification of p110 isoform is shown on the right, showing dramatically reduced p110 in Adar G1007R/G1007R ; Ifih1 −/− brains. Data are presented as mean ± SD, n = 3. The Prism t test was used to test the differences between the two groups. ∗∗∗ p < 0.001. (C) cDNA alignment shows altered sequences. The cDNA clones of the E11.5-day Adar G1007R/G1007R embryonic total RNAs were subjected to Sanger sequencing. The cDNA sequences covering the region of exon 10 to exon 13 are compared between the Adar G1007R/G1007R and WT embryos . The sequences of the corresponding exons are indicated by alternative colors. The G>A mutation site is highlighted in red and boxed. The dashes indicate the missing sequences, including the missing exon 11, exon 12, or the 27 nucleotides in 3′end of exon 11. The seven extra nucleotides highlighted in blue are from intron 11. Five different mRNA sequences containing different exons or intron are shown here. (D) The genetic G>A mutation (G1007R) at 3′ end of exon 11 in the Adar gene alters the TG splice donor site sequence to TA. A chromatogram from Sanger sequencing of a heterozygous genome flanking the mutation site is shown. The donor site is boxed, and the mutation is indicated by an arrow.

Article Snippet: Nine independent RNA libraries were generated using the KAPA RNA HyperPrep Kit with the removal of ribosome RNAs by RiboErase (Kapa Biosystems) according to the manufacturer’s protocol, and the libraries were sequenced using the NovaSeq6000 platform (Illumina) to an average of 80M 10o bp paired end reads.

Techniques: Mutagenesis, Alternative Splicing, Western Blot, Isolation, Clone Assay, Sequencing

Alternative splicing caused by the G1007R mutation (A) Comparison of normal splicing (splicing 1, SP1, between exon 11 and 12) to identified variants. The other four splicing variants (SP2-5) do not occur at the donor site of exon 11. The genome structure from exon 10 to 13 at the Adar locus, along with the splicing site sequences, is shown here. The A>G mutation at the donor site of exon 11 is highlighted in red. The −27 splicing site in Exon 11 and the +7 splicing site in intron 11 are indicated. Splicing pattern 1 (SP1) comprised intact exon 11 and exon 12. Splicing patterns 2–5 skip exons or use alternative splicing sites, generating RNA transcripts of different lengths. (B) Sequences surrounding the splicing sites of the five alternative splicing patterns. Exonic sequences are indicated in red, while intronic sequences are shown in blue. The seven nucleotides of intron 11 are shaded, and the splicing donor sites are boxed. The corresponding Sanger sequencing results of the cDNA clones of the alternatively spliced mRNAs are presented in . (C) Comparison of WT and Adar G1007R/G1007R ; Ifih1 −/− RNA transcripts. The total RNA-seq reads transcribed from exon 10–13 at Adar locus are compared between the WT and Adar G1007R/G1007R ; Ifih1 −/− mice at two weeks of age. There is significantly less RNAs transcribed from the G1007R mutant Adar alleles. Data are presented as mean ± SD, n = 3, and the Prism t test was used to test the differences between the two groups. ∗ p < 0.05. (D) The numbers of the spliced and non-spliced RNAs were compared between the WT and Adar G1007R/G1007R ; Ifih1 −/− mice. The number of the spliced RNAs is dramatically less in the Adar G1007R/G1007R ; Ifih1 −/− mice than the WT mice, while there are more non-spliced RNAs (contain intron sequences) in the G1007R mutant mice. Data are presented as mean ± SD, n = 3, and the Prism t test was used to test the differences between the two groups. ∗∗∗ p < 0.001. (E) Alignment of the spliced RNAs in RNA-seq data mapping to exons 10–13 of Adar . RNA reads from one of the Adar G1007R/G1007R ; Ifih1 −/− mouse is shown. The colored boxes represent the RNA sequences and lines represent the intron sequences that do not present in the RNA reads. Different colors show the various splicing patterns. (F) Relative quantities of each spliced type. Data were calculated according to the numbers of each spliced RNA read in three Adar G1007R/G1007R ; Ifih1 −/− mice. The average of the percentile of each splicing type is shown. The splicing between exon 11 and 12 is the most frequent, followed by the splicing skipping exon 11. The splicing skipping of exons 11 and 12 is the least frequent among these five alternative splicing patterns. The −27 and +7 splicing comprise less than 20% of the total spliced RNAs for each splicing type. (G) Comparison of ADAR1 RNAs spliced at exon 11 and 12 (SP1) between the WT and Adar G1007R/G1007R ; Ifih1 −/− mice. SP1 is significantly decreased in Adar G1007R/G1007R ; Ifih1 −/− mice than the WT controls. Data are presented as mean ± SD, n = 3, the Prism t test was used to test the differences between the two groups. ∗∗∗ p < 0.001.

Journal: iScience

Article Title: Heterozygous ADAR mutant mice exhibit RNA sensing-dependent neuroinflammation and phenotypes associated with Aicardi-Goutières syndrome

doi: 10.1016/j.isci.2026.114758

Figure Lengend Snippet: Alternative splicing caused by the G1007R mutation (A) Comparison of normal splicing (splicing 1, SP1, between exon 11 and 12) to identified variants. The other four splicing variants (SP2-5) do not occur at the donor site of exon 11. The genome structure from exon 10 to 13 at the Adar locus, along with the splicing site sequences, is shown here. The A>G mutation at the donor site of exon 11 is highlighted in red. The −27 splicing site in Exon 11 and the +7 splicing site in intron 11 are indicated. Splicing pattern 1 (SP1) comprised intact exon 11 and exon 12. Splicing patterns 2–5 skip exons or use alternative splicing sites, generating RNA transcripts of different lengths. (B) Sequences surrounding the splicing sites of the five alternative splicing patterns. Exonic sequences are indicated in red, while intronic sequences are shown in blue. The seven nucleotides of intron 11 are shaded, and the splicing donor sites are boxed. The corresponding Sanger sequencing results of the cDNA clones of the alternatively spliced mRNAs are presented in . (C) Comparison of WT and Adar G1007R/G1007R ; Ifih1 −/− RNA transcripts. The total RNA-seq reads transcribed from exon 10–13 at Adar locus are compared between the WT and Adar G1007R/G1007R ; Ifih1 −/− mice at two weeks of age. There is significantly less RNAs transcribed from the G1007R mutant Adar alleles. Data are presented as mean ± SD, n = 3, and the Prism t test was used to test the differences between the two groups. ∗ p < 0.05. (D) The numbers of the spliced and non-spliced RNAs were compared between the WT and Adar G1007R/G1007R ; Ifih1 −/− mice. The number of the spliced RNAs is dramatically less in the Adar G1007R/G1007R ; Ifih1 −/− mice than the WT mice, while there are more non-spliced RNAs (contain intron sequences) in the G1007R mutant mice. Data are presented as mean ± SD, n = 3, and the Prism t test was used to test the differences between the two groups. ∗∗∗ p < 0.001. (E) Alignment of the spliced RNAs in RNA-seq data mapping to exons 10–13 of Adar . RNA reads from one of the Adar G1007R/G1007R ; Ifih1 −/− mouse is shown. The colored boxes represent the RNA sequences and lines represent the intron sequences that do not present in the RNA reads. Different colors show the various splicing patterns. (F) Relative quantities of each spliced type. Data were calculated according to the numbers of each spliced RNA read in three Adar G1007R/G1007R ; Ifih1 −/− mice. The average of the percentile of each splicing type is shown. The splicing between exon 11 and 12 is the most frequent, followed by the splicing skipping exon 11. The splicing skipping of exons 11 and 12 is the least frequent among these five alternative splicing patterns. The −27 and +7 splicing comprise less than 20% of the total spliced RNAs for each splicing type. (G) Comparison of ADAR1 RNAs spliced at exon 11 and 12 (SP1) between the WT and Adar G1007R/G1007R ; Ifih1 −/− mice. SP1 is significantly decreased in Adar G1007R/G1007R ; Ifih1 −/− mice than the WT controls. Data are presented as mean ± SD, n = 3, the Prism t test was used to test the differences between the two groups. ∗∗∗ p < 0.001.

Article Snippet: Nine independent RNA libraries were generated using the KAPA RNA HyperPrep Kit with the removal of ribosome RNAs by RiboErase (Kapa Biosystems) according to the manufacturer’s protocol, and the libraries were sequenced using the NovaSeq6000 platform (Illumina) to an average of 80M 10o bp paired end reads.

Techniques: Alternative Splicing, Mutagenesis, Comparison, Sequencing, Clone Assay, RNA Sequencing